EUVIMEDOpdag EUVIMED
Crossref

Claudin‐4 immunocytochemistry is specific and sensitive for the diagnosis of malignant carcinomatous effusions: Results from a pilot study

Vanlal Hruaii, Balamurugan Thirunavukkarasu iD, Vindhya Prabha, Sandeep Mathur, Venkateswaran K Iyer, Aruna Nambirajan, Deepali Jain iD

Diagnostic Cytopathology · 2024

DOI: 10.1002/dc.25238 ↗

At a glance

Journal article in Diagnostic Cytopathology, 2024. Written by Vanlal Hruaii and 6 co-authors. Institution: Department of Pathology, All India Institute of Medical Sciences, New Delhi, India. Major MEDLINE topics: Carcinoma, Adenocarcinoma, Mesothelioma, Pleural Effusion, Malignant. Cited 3 times so far (Crossref); 28 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Claudin‐4, a tight junction associated protein expressed in epithelial cells, is purported as a highly specific and sensitive marker for epithelial malignancies. Our aim was to assess the sensitivity, specificity and real‐time utility of claudin‐4 immunocytochemistry (ICC) in the diagnostic work‐up of suspected malignant effusions.

Methods

Claudin‐4 (3E2C1 clone) ICC was performed prospectively in effusion cell blocks where other ICC markers were being performed as part of reporting over 3 months. Based on claudin‐4 staining in unequivocal malignant and reactive effusions, the sensitivity and specificity was calculated. In cases signed out as inconclusive encompassing atypia of undetermined significance (AUS) and suspicious for malignancy (SFM) and negative for malignancy, change in diagnostic category based on addition of claudin‐4 ICC was assessed.

Results

Study included 107 effusions. Claudin‐4 stained 100% of metastatic adenocarcinomas including those with primaries in lung, breast, ovary, female genital tract, gastrointestinal tract and pancreatic‐biliary tract, and was negative in all reactive mesothelial and mesothelioma effusions with sensitivity of 100% (48/48) and specificity of 95% (20/21) for adenocarcinoma. Claudin‐4 upgraded the diagnostic category to positive in 70% (16/23) of SFM, 20% (1/5) of AUS, and in 50% (5/10) of negative effusions. Among cases with confirmed serosal involvement status on follow‐up, claudin‐4 showed sensitivity, specificity, positive predictive value and negative predictive values of 85% (11/13), 100% (3/3), 100% (10/10) and 75% (3/4), respectively, for metastatic adenocarcinoma.

Conclusion

Claudin‐4 as a single marker is sensitive and specific for adenocarcinoma and is a valuable addition to the ICC armamentarium.

Subjects

MeSH terms (MEDLINE)

CarcinomaAdenocarcinomaMesotheliomaPleural Effusion, MalignantHumansFemaleClaudin-4Pilot ProjectsImmunohistochemistryBiomarkers, TumorDiagnosis, Differential

Author keywords

carcinomacell blockclaudin-4effusionimmunochemistrymesothelioma

Substances

Claudin-4Biomarkers, Tumor

Authors and institutions

  • Department of Pathology, All India Institute of Medical Sciences, New Delhi, India.

ORCID profiles: Balamurugan Thirunavukkarasu, Deepali Jain

Cite

APA

Hruaii, V., Thirunavukkarasu, B., Prabha, V., Mathur, S., Iyer, V. K., Nambirajan, A., & Jain, D. (2024). Claudin‐4 immunocytochemistry is specific and sensitive for the diagnosis of malignant carcinomatous effusions: Results from a pilot study. Diagnostic Cytopathology. https://doi.org/10.1002/dc.25238

Vancouver

Hruaii V, Thirunavukkarasu B, Prabha V, Mathur S, Iyer VK, Nambirajan A, et al. Claudin‐4 immunocytochemistry is specific and sensitive for the diagnosis of malignant carcinomatous effusions: Results from a pilot study. Diagnostic Cytopathology. 2024. doi:10.1002/dc.25238

BibTeX
@article{Hruaii2024,
  author = {Hruaii, Vanlal and Thirunavukkarasu, Balamurugan and Prabha, Vindhya and Mathur, Sandeep and Iyer, Venkateswaran K and Nambirajan, Aruna and Jain, Deepali},
  title = {Claudin‐4 immunocytochemistry is specific and sensitive for the diagnosis of malignant carcinomatous effusions: Results from a pilot study},
  journal = {Diagnostic Cytopathology},
  year = {2024},
  doi = {10.1002/dc.25238}
}
Start for free →